No controlled studies exist regarding the pharmaceutical reduction of ataxia symptoms in ataxia telangiectasia (A-T). In a multicenter, double-blind, randomized, placebo-controlled crossover trial, oral betamethasone (BETA) and placebo were compared in terms of their reduction of ataxia symptoms as assessed with the International Cooperative Ataxia Rating Scale (ICARS). In this study of 13 A-T children, betamethasone reduced the ICARS total score by a median of 13 points in the intent-to-treat population and 16 points in the per-protocol population (ie, median percent decreases of ataxia symptoms of 28% and 31%, respectively). In conclusion, Oral betamethasone could be a promising therapy to relieve ataxia symptoms in A-T patients; however, long-term effectiveness and safety must be established

A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia / R. Zannolli, S. Buoni, G. Betti, S. Salvucci, A. Plebani, A. Soresina, M.C. Pietrogrande, S. Martino, V. Leuzzi, A. Finocchi, R. Micheli, L.N. Rossi, A. Brusco, F. Misiani, A. Fois, J. Hayek, C. Kelly, L. Chessa. - In: MOVEMENT DISORDERS. - ISSN 0885-3185. - 27:10(2012 Sep 01), pp. 1312-1316.

A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia

M.C. Pietrogrande;L.N. Rossi;
2012

Abstract

No controlled studies exist regarding the pharmaceutical reduction of ataxia symptoms in ataxia telangiectasia (A-T). In a multicenter, double-blind, randomized, placebo-controlled crossover trial, oral betamethasone (BETA) and placebo were compared in terms of their reduction of ataxia symptoms as assessed with the International Cooperative Ataxia Rating Scale (ICARS). In this study of 13 A-T children, betamethasone reduced the ICARS total score by a median of 13 points in the intent-to-treat population and 16 points in the per-protocol population (ie, median percent decreases of ataxia symptoms of 28% and 31%, respectively). In conclusion, Oral betamethasone could be a promising therapy to relieve ataxia symptoms in A-T patients; however, long-term effectiveness and safety must be established
Administration, Oral ; Adolescent ; Anti-Inflammatory Agents ; Ataxia Telangiectasia ; Betamethasone ; Child ; Female ; Humans ; Male ; Treatment Outcome
Settore MED/38 - Pediatria Generale e Specialistica
Settore MED/39 - Neuropsichiatria Infantile
1-set-2012
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/225922
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 74
  • ???jsp.display-item.citation.isi??? 69
social impact